The presence of T cells at the tumor site is critical for immune recognition and elimination of AML cells, and a higher percentage of CD8+ T cells in BM were predictive of responses to ICIs combined with a hypomethylating agent in AML patients (3, 35). This evidence concerns the gene CD8A and acute myeloid leukemia.